October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement